kgro - While your stratement that "zero" countries "went for" Leronlimab is true, in my opinion it's not any sort of proof that Leronlimab is a failure.
Two reasons why:
1) That exact same statement was applicable to every single drug at one point in its development. EVERY one.
2) You can add one small word to the sentence, completely altering its meaning yet still maintaining its truthfulness: "Zero countries went for Leronlimab yet."
Because it was an M/M trial NOT S/C which is what the world needed at the time. NOW, CD10 seems to be getting attention. I reference the Long Haulers, for one. See, the P2 trial gives all kinds of information to drug companies so they plan for P3 trials.
Market Data 
Markets 
AI
